Petros Pharmaceuticals

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx

Cumberland Pharma

Nautilus Biotechnology

Are these on your list of penny stocks to buy this week? The post Penny Stocks To Buy This Week: 4 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy This Week: 4 To Watch Right Now

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offering and private placement with the company's largest investor and other existing investors for gross proceeds of approximately 10.0 million. Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform and for working capital and general corporate purposes.

Petros Pharmaceuticals Announces Closing of $10 Million Offering

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has entered into definitive agreements with the company's largest investor and other existing investors, for the purchase and sale of 3,333,333 shares of Petros Pharmaceuticals' common stock, at a purchase price of $3.00 per share. The company will sell 2,153,333 shares in a registered direct offering and the remaining 1,180,000 shares will be sold in a private placement.

Petros Pharmaceuticals Announces $10 Million Offering

The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by 91.39% in the most trading session. This is why it happened.

Petros Pharmaceuticals (PTPI) Stock: Why The Price Surged

Petros Pharmaceuticals Inc (NASDAQ: PTPI) is soaring on abnormally high volume Monday despite no apparent news catalyst.  Petros Pharmaceuticals' average session volume is about 6.4 million over a 100-day period.

What's Going On With Petros Pharmaceuticals Stock Today?

Avenue Therapeutics

Shares of penny stocks PTPI & ATXI are on the move and here's what's going on. The post Best Penny Stocks Today: Why ATXI & PTPI Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks Today: Why ATXI & PTPI Stock Are Moving

Petros Pharmaceuticals (PTPI) stock is taking off in pre-market trading on Monday as short-squeeze talk on social media pushes shares higher. The post PTPI Stock: The Short-Squeeze Buzz That Has Petros Pharmaceuticals Rocketing Today appeared first on InvestorPlace.

PTPI Stock: The Short-Squeeze Buzz That Has Petros Pharmaceuticals Rocketing Today

The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by over 90% pre-market today. This is why it happened.

Petros Pharmaceuticals (PTPI) Stock: Why The Price Surged Today

Enel Chile

Qualigen Therapeutics

If you're making a penny stocks watchlist for December, check these three out The post Hot Penny Stocks to Add to Your Watchlist in December appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Add to Your Watchlist in December

Petros Pharmaceuticals (PTPI) stock is surging higher on Tuesday following a filing with the U.S. Securities and Exchange Commission (SEC). The post PTPI Stock: 11 Things to Know About Penny Stock Petros Pharmaceuticals as Shares Rocket 100%+ appeared first on InvestorPlace.

PTPI Stock: 11 Things to Know About Penny Stock Petros Pharmaceuticals as Shares Rocket 100%+

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results for the third quarter ended September 30, 2021. Recent Highlights: Total STENDRA® prescription and tablet sales hit record levels in Q3 Total STENDRA® mg sold in Q3 increased 6% over Q2, which was up 4% over Q1, showing continuing momentum in the market Completed pilot label comprehension study to initiate process for STENDRA® prescription erectile dysfunction medication to support the process for designation as over -the-counter treatment Enrolled Phase 2 Label Comprehension Study Progressing the Process for STENDRA® Prescription Erectile Dysfunction Medication to Achieve Designation as an over-the-counter treatment Entered exclusive marketing agreement with Hims & Hers Health expanding dosages offered on their telehealth platform Expanded program for novel investigational non-invasive treatment formulation for Peyronie's disease "Petros continued its momentum during the third quarter with the number of prescriptions and tablets hitting record levels.

Petros Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021. Mr. Boctor will deliver his corporate presentation on Wednesday, November 17 at 1:15 PM ET.

Petros Pharmaceuticals to Present at the Q4 Investor Summit Conference

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today the expansion of its program for investigational H100, a novel patented non-invasive topical treatment under development for Peyronie's disease. H100 is a topical gel formulated to address the inflammatory cascade that leads to pain, scarring and penile irregularities associated with Peyronie's disease.

Petros Pharmaceuticals Expands Program for Novel Investigational Non-Invasive Treatment Formulation for Peyronie's Disease

Today, investors in Petros Pharmaceuticals and PTPI stock are cheering a telemedicine agreement, sending shares of this company skyrocketing. The post PTPI Stock: The Huge Reason Little-Known Petros Pharmaceuticals Is Gaining Today appeared first on InvestorPlace.

PTPI Stock: The Huge Reason Little-Known Petros Pharmaceuticals Is Gaining Today

Petros Pharmaceuticals Inc (NASDAQ: PTPI) is trading higher Wednesday after the company announced 476% growth year-over-year of STENDRA tablet sales as part of its digital marketing agreement with Hims & Hers Health Inc (NYSE: HIMS). The companies also announced the availability of additional dosages of STENDRA through the Hims & Hers platform, further expanding the partnership.

Why Petros Pharmaceuticals Stock Is Soaring Today

Allena Pharmaceuticals

Uranium Energy

Which penny stocks are you watching as GME stock and AMC stock shoot toward the moon? The post Hot Penny Stocks to Watch as AMC and GME Go to the Moon appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch as AMC and GME Go to the Moon

NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Petros, Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces a 476% growth year-over-year of STENDRA tablet sales as part of an exclusive digital health marketing agreement with Hims & Hers Health, Inc. ("Hims & Hers" or "Hims"), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers. The companies also announce the availability of additional dosages of STENDRA through the Hims & Hers platform, further expanding the partnership.

Petros Pharmaceuticals, Inc. Through Exclusive Marketing Agreement with Hims & Hers Health, Inc. Generates 476% Year-Over-Year Growth of STENDRA Tablet Sales

NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offering with the company's largest and other existing investors for gross proceeds of approximately $5.7 million. Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform and for working capital and general corporate purposes.

Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has entered into definitive agreements with the company's largest investor and other existing investors, for the purchase and sale of 3,323,616 shares of Petros Pharmaceuticals' common stock, at a purchase price of $1.715 per share, in a registered direct offering. Petros Pharmaceuticals has also agreed to issue to the investors unregistered warrants to acquire 3,323,616 shares of common stock at $1.715 per share, exercisable immediately and terminating 5 years after the date of issuance.

Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present at the H.C.

Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results for the second quarter ended June 30, 2021. Second Quarter Highlights: Completed pilot label comprehension study to initiate process for STENDRA prescription erectile dysfunction medication to support the process for designation as over -the-counter treatment Initiated communications with the U.S. Food and Drug Administration regarding expansions to STENDRA's package insert (label) STENDRA® net sales increased 123% during the second quarter of 2021 vs.

Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Increase in Year Over Year Quarterly STENDRA® (avanafil) Net Sales

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor is scheduled to present at the following virtual conferences: Q3 Investor Summit:  August 17 – 18, 2021 Mr. Boctor will deliver his corporate presentation on August 17 at 12:30 pm ET.

Petros Pharmaceuticals to Present at Two Upcoming August Conferences

New Jersey and Pennsylvania--(Newsfile Corp. - August 11, 2021) - Petros Pharmaceuticals (NASDAQ: PTPI) today announced that Fady Boctor, President, Chief Commercial Officer will be attending the Q3 Virtual Investor Summit.  Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 17th at 12:30 PM ET

Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit

NEW YORK, July 12, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021. Mr. Boctor will deliver his corporate presentation on July 14 at 3:30pm ET.

Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021

NEW YORK, June 2, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021. Mr. Boctor will deliver his corporate presentation on June 10 at 4:00pm ET, Track 1.

News for Petros Pharmaceuticals Stock (PTPI)